0001493152-22-014659.txt : 20220520
0001493152-22-014659.hdr.sgml : 20220520
20220520181557
ACCESSION NUMBER: 0001493152-22-014659
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220518
FILED AS OF DATE: 20220520
DATE AS OF CHANGE: 20220520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mack Anthony P.
CENTRAL INDEX KEY: 0001818483
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40064
FILM NUMBER: 22949107
MAIL ADDRESS:
STREET 1: C/O VIRPAX PHARMACEUTICALS, INC.
STREET 2: 1554 PAOLI PIKE #279
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Virpax Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001708331
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 821510982
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1554 PAOLI PIKE #279
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
BUSINESS PHONE: 484-875-3195
MAIL ADDRESS:
STREET 1: 1554 PAOLI PIKE #279
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
FORMER COMPANY:
FORMER CONFORMED NAME: Virpax Pharmaceuticals Inc.
DATE OF NAME CHANGE: 20170602
4
1
ownership.xml
X0306
4
2022-05-18
0
0001708331
Virpax Pharmaceuticals, Inc.
VRPX
0001818483
Mack Anthony P.
1055 WESTLAKES DRIVE,
SUITE 300
BERWYN
PA
19312
1
1
0
0
Chief Executive Officer
Common Stock, $0.00001 par value
2022-05-18
4
P
0
75750
1.34
A
252562
D
Common Stock, $0.00001 par value
2730438
I
By Virpax Pharmaceuticals, LLC
The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices ranging from $1.32 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Virpax Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
The Reporting Person owns 88.8888% of the outstanding member units of Virpax Pharmaceuticals, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
/s/ Christopher Chipman, attorney-in-fact
2022-05-20